tbuckley/cabot-search huggingface dataset:
St. Mary's Hospital
Authors: C. H. Jones
Journal: BMJ (1862)

of our human nature; and the extent of this igno- rance and amount of this degraded weakness must, alas! be measured by the amazing spread of quackery amongst the masses of mankind.The homoeopath talks of infinitesimal doses, and flourishes a few un- meaning cabalistic phrases; and finds abundant lis- teners, because he flatters, he promises, and, above all, gabbles to the people of that which is utterly incomprehensible to them.If the bright face of medicine be ever obscured by the shadow of quackeries and delusions, it can only be in proportion as our professional morality has grown weak.But woe is it to our art when men are found amongst us who are willing to shake hands with a wicked imposture, because, clothed in the garb which it has surreptitiously stolen from medicine, this imposture has found favour in the eyes of the wealthy!Woe, is it to our art when men barter their professional honour for the sake of great gains, or juggle their consciences with jesuitical rules of ethics !But, gentlemen, thank Heaven !our body is sound at heart.If a loose professional morality be here and there seen floating about amongst us, we know and feel, as members of a medical corporation, that our path and course are clear and fixed amidst this scene of ignorance and vicious reasonings.It is no fault of ours if deception in the cure of dis- eases have a strong hold on the human mind.Let us only keep our hands clean of the contagion of pan- dering to it.We have no reason to fear the conclusion.Truth is stronger than deception.
Acta Endocrinologica, Copenhagen
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contempo 79
Authors: M. T. Southgate
Journal: JAMA (1979)

LAST year we published a special issue ofThe JOURNAL(Feb 6, 1978) in which each member of our Editorial Board capsuled into a thousand words or so two or three of the noteworthy aspects of his specialty at that time. The result was a tidy little package of some 30 pages that contained the essence of the experience of our Board members. We called the issue COMTEMPO, a name we chose deliberately because it had no dictionary definition. Our goal was not to limit but to stimulate. We even hoped that the issue might become an annual feature. Well before the issue was a month old we knew that there would have to be a next issue and that it would have to be considerably expanded. Whereas there are some 40 officially recognized specialties and subspecialties in medicine, we could cover less than half that number without going beyond
Committees.
Authors: P Rhodes
Journal: BMJ (1983)

Formal administration is done in committees, which may be ad hoc and called for a specific purpose or may be standing committees, since problems are always cropping up asking for their attention.Departmental meetings, cogwheel divisions, and regional medical advisory committees are all standing com- mittees.Of special interest are the regional hospital junior staff committees, which continually keep an eye on all things of concern to junior doctors and feed their anxieties and delibera- tions into many other regional committees.Ad hoc committees may be set up, for example, to decide what form of radiological equipment to buy for a particular hospital or whether a new department should be set up.Never miss the opportunity to serve on a few committees.The experience is invaluable.It will teach you much about your fellow doctors, and you will learn techniques of how to persuade others to your point of view.As you become more senior you will find that this more and more becomes part of your duties.You fight for your corner, whatever you conceive that to be.If you do not your voice will go unheard and actions will be taken that are detrimental to you and your responsi- bilities.Others will get staff and resources for their work because you have not been bothered to understand and work the system to your own and your enterprise's advantage.You may deplore this but you had better know that this is how it works.Only rarely will others take care of your interests.You must look to them yourself.In medicine it is not viciousness on the part of colleagues that does you down.It is simply that some push their cases harder than others, and if you do not take part your case will go by default.The duties of a doctor must be a judicious mixture of service to patients, research, and teaching-and administration to make the first three fully effective.Neglect of any of the four means poorer functioning so that patients, staff, and students (undergraduate and graduate) lose out compared with others.All four must be properly pursued and prosecuted.
Errors in Abstract, Main Text, and Supplement 1
Journal: JAMA Network Open (2022)

Marla K. Beauchamp, PhD; Divya Joshi, PhD; Jacqueline McMillan, MD; Urun Erbas Oz, PhD; Lauren E. Griffith, PhD; Nicole E. Basta, PhD; Susan Kirkland, PhD; Christina Wolfson, PhD; Parminder Raina, PhD; Canadian Longitudinal Study on Aging (CLSA) Team; Andrew Costa; Laura Anderson; Cynthia Balion; Asada Yukiko; Benoȋt Cossette; Melanie Levasseur; Scott Hofer; Theone Paterson; David Hogan; Teresa Liu-Ambrose; Verena Menec; Philip St. John; Gerald Mugford; Zhiwei Gao; Vanessa Taler; Patrick Davidson; Andrew Wister; Theodore Cosco
Personal View
Authors: J D Hill
Journal: BMJ (1986)

Personal View3 00 pm, Tuesday.Sharon*, a 19 year old girl, is admitted unconscious.The diagnosis of subarachnoid haemorrhage is not difficult to make and it rapidly becomes clear to the doctors and nurses that her prognosis is grave; organ donation becomes a possibility.She does carry a donor card. 530 pm, Tuesday.At the end of a busy clinic I explain to Sharon's mother, remarried for three weeks and bewildered by the appalling disaster facing her, how Sharon may yet survive and that we will do everything in our power to save her.Angiography is an option to be considered if she regains consciousness but, at the time, transport to the local neurosurgical unit is too dangerous.We must give her intensive support and wait.
Medical manpower.
Authors: P R Vickers
Journal: BMJ (1977)

We welcome your rapid responses, whether in direct response to an article in Career Focus or as a way of sharing your own ideas. As long as it isn9t libellous or offensive, we9ll post it on our website. We print a selection of rapid reponses here and the writer of the best each month wins an <i>Oxford Handbook</i> of their choice. Letter of the month prize is donated by OUP.
Abstract 110: The Dynamic Clinical Course of Resuscitation in Children With Cardiac Arrest
Authors: Trond Nordseth, Dana Niles, Trygve Eftestøl, Vinay Nadkarni, Robert Sutton, Robert Berg, Unai Irusta, Jan T Kvaløy, Benjamin S Abella, Eirik Skogvoll
Journal: Circulation (2018)

Background: During cardiac arrest, a child may be in one of five clinical states (“rhythms”): 1) Bradycardia with poor perfusion; 2) Pulseless Electrical Activity (PEA); 3) Ventricular Fibrillation or Pulseless Ventricular Tachycardia (VF/VT); 4) Asystole; or 5) Spontaneous Circulation (ROSC). The aim of study was to investigate and quantify the dynamic characteristics of this process. Methods: We prospectively acquired data on rhythm and clinical states using recording defibrillators during active CPR. Recordings were analyzed as a multi-state statistical model, focusing on transitions between PEA (including bradycardia with poor perfusion), VF/VT, Asystole, and ROSC (defined as an organized electrical rhythm without chest compressions &gt;= 1 minute). Instantaneous transition rates were obtained by smoothing the Nelson-Aalen estimator of cumulative intensities. Results: In 74 Cardiac Arrest events with evaluable data, median patient age was 15 years [range 1.75 to 22.9; IQR 11 to 17]. Fifty percent had a respiratory etiology and 51 % were female. PEA was the most frequent presenting cardiac arrest rhythm (38 %); followed by VF/VT (24 %), bradycardia (22 %), and asystole (16 %). Starting from time of defibrillator attachment (median 3 minutes into the event) as shown in the figure that shows 45 minutes of CPR, the prevalence of sustained ROSC reached an asymptotic value of 30 % at 20 minutes. We observed a temporary surge of PEA at about 12 minutes, resulting from a doubling (from 0.1 to 0.2 transitions/min) of the instantaneous transition rate of ROSC to PEA during this period. Conclusion: We provide a quantitative overview of the dynamic process of clinical state transitions during in-hospital cardiac arrest and resuscitation in older children and adolescents. A notable feature was a temporary increase in the prevalence of PEA at 12 minutes.
Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma.
Authors: Xieqiao Yan, Siming Li, Zhihong Chi, Lu Si, Chuanliang Cui, Yan Kong, Li Zhou, Bixia Tang, Xiaowen Wu, Lili Mao, Xuan Wang, Bin Lian, Xue Bai, Jie Dai, Jun Guo, Xinan Sheng
Journal: Journal of Clinical Oncology (2022)

341 Background: Xp11.2 translocation renal cell carcinoma (RCC) is a unique RCC subtype with high malignant potential and poor prognosis, its natural course and response to systemic therapy are not fully understood. We analyzed the clinic features of this distinct entity and the benefit of systemic therapy in these patients. Methods: Between May 2006 and December 2019, 1113 consecutive patients diagnosed with RCC from Peking university cancer hospital (Beijing, China) were reviewed, data of the clinical characteristics and outcome of patients with metastatic Xp11.2 RCC were retrospectively collected. Tumor response to systemic therapy was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS) distributions. Results: Metastatic Xp11.2 tRCC was found in 45 patients. The median PFS and median OS was 7.4 months (4.5 - 8.8) and 17.9 months (12.4 - 24.4), respectively. First-line treatment mainly included sunitinib (n = 14), sorafenib (n = 15), axitinib (n = 6), and pazopanib (n = 5), and the median PFS of these regimens were 7.4 months, 5.4 months, 9.4 months, 8.9 months, respectively. Two patients who received Vascular endothelial growth factor receptor - tyrosine kinase inhibitor (VEGFR-TKI) plus immune checkpoint inhibitor (ICI) as first line therapy had a PFS of more than 16.6 months and more than 25.6 months, respectively. Twenty-four patients received subsequent therapies, which included VEGFR-TKI/ICI, axitinib and mTOR inhibitor, the median PFS for these regimens was 8.5, 7.2 and 2.0 months, respectively. Patients with serous cavity effusion or IMDC poor risk groups had significantly shorter median PFS and median OS. Conclusions: Metastatic Xp11.2 tRCC is an aggressive disease. VEGFR-TKI agents appeared to demonstrate some efficacy, VEGFR-TKI/ICI combination might be a useful tool for the treatment of metastatic Xp11.2 tRCC.
Peripheral Regeneration
Authors: Zu-Lin Chen, Wei-Ming Yu, Sidney Strickland
Journal: Annual Review of Neuroscience (2007)

Whereas the central nervous system (CNS) usually cannot regenerate, peripheral nerves regenerate spontaneously after injury because of a permissive environment and activation of the intrinsic growth capacity of neurons. Functional regeneration requires axon regrowth and remyelination of the regenerated axons by Schwann cells. Multiple factors including neurotrophic factors, extracellular matrix (ECM) proteins, and hormones participate in Schwann cell dedifferentiation, proliferation, and remyelination. We describe the current understanding of peripheral axon regeneration and focus on the molecules and potential mechanisms involved in remyelination.
Comment on Timing of Surgery For Patients With Rectal Cancers Not Responding to Preoperative Chemoradiation—Reply
Authors: Simona Deidda, Gaya Spolverato, Angelo Restivo
Journal: JAMA Surgery (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis: Erratum
Authors: Wenzhi Shen, Xiaoyuan Zhang, Jiaping Tang, Zhixin Zhang, Renle Du, Dehong Luo, Xiaoran Liu, Yong Xia, Yanping Li, Shanshan Wang, Siyuan Yan, Wancai Yang, Rong Xiang, Na Luo, Yunping Luo, Jianjun Li
Journal: Theranostics (2021)
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations—Urothelial cancer cohort (trial in progress).
Authors: Matt D. Galsky, Jorge Ramos, Qianwen Tan, Evan Y. Yu
Journal: Journal of Clinical Oncology (2022)

TPS586 Background: Tucatinib, a highly selective HER2-directed tyrosine kinase inhibitor approved in multiple regions for HER2+ metastatic breast cancer, is being investigated as a novel therapy for metastatic colorectal cancer, gastric cancer, and other GI tumors. In xenograft models of HER2+ and HER2-mutated tumors, dual targeting of HER2 with tucatinib and trastuzumab showed superior activity to either alone (Kulukian 2020; Peterson 2020 ). Despite development of several new therapies for metastatic urothelial cancer, most patients do not respond to subsequent therapies, and majority of patients succumb to the disease, highlighting the need for additional therapeutic approaches. Given 20%-30% of metastatic urothelial cancers have molecular alterations of the ErbB family, tucatinib + trastuzumab warrants further evaluation. SGNTUC-019 (NCT04579380) is a multi-cohort, open-label, international Phase 2 study evaluating tucatinib + trastuzumab in patients with previously treated solid tumors displaying HER2+ or HER2-mutated solid tumors, including a cohort with locally advanced or metastatic urothelial cancer (UC). Methods: Eligible patients must have HER2+ or HER2-mutated locally advanced or metastatic solid tumors, with progression on or after the last systemic therapy for advanced disease. Additionally, patients must have an ECOG PS ≤1, adequate hepatic, hematologic, renal, and cardiac function, and no prior exposure to HER2-directed therapy in the UC cohort. For eligibility, HER2 alterations can be demonstrated by HER2 overexpression/amplification in tumor tissue by prior IHC/ISH, or by HER2 amplification/mutation in prior or pre-screening NGS assay of ctDNA or prior tissue NGS assay. The HER2 overexpression/amplification UC cohort will enroll 12 response-evaluable patients per RECIST 1.1. If ≥2 responses are observed, the cohort will be expanded to 30. Patients with HER2-mutated UC will be enrolled into a cohort of 30 patients with HER2-mutated solid tumors (except breast and non-squamous non-small cell lung cancers). The primary objective is antitumor activity, with confirmed ORR as the primary endpoint, and disease control rate, duration of response, PFS, and OS as secondary efficacy endpoints. Patients will receive tucatinib 300 mg orally twice daily and trastuzumab 8 mg/kg intravenous on Cycle 1 Day 1 and 6 mg/kg q21 days from Cycle 2 Day 1. Disease assessments per RECIST 1.1 will occur q6 weeks for 24 weeks, then q12 weeks. Trough concentrations of tucatinib will be evaluated in Cycles 2-6, with a peak concentration sampled in Cycle 3. Quality of life will be evaluated q2 cycle using EQ-5D-5L. Sites are currently enrolling within the US, EU, and Asia Pacific. Clinical trial information: NCT04579380.
Lung transplantation.
Authors: L D MacLean
Journal: Thorax (1969)

Proceedings of the Thoracic Society 0.8 mg./kg., was given.Of the 10 patients treated, four were completely relieved, five were partially relieved, and only one showed no response.The speed of response varied from one to 10 days.Symptomatic improvement was notable.The duration of relief varied from four weeks to eight months.Recurrence of superior vena caval obstruction needing further treatment was seen in two of these patients, and another patient died of recurrent superior vena caval obstruction.It is felt that the results of this small series warrant further consideration of this readily available method of treatment as an alternative to radiotherapy.
Successful same-day discharge for robot-assisted radical prostatectomy: A systematic review and meta-analysis.
Authors: Michael Uy, Braden Millan, Conor Jones, David Sands, Edward Matsumoto, Benjamin Bay, Bobby Shayegan
Journal: Journal of Clinical Oncology (2022)

238 Background: In the current era of enhanced recovery after surgery (ERAS), same day discharge (SDD) following robot-assisted radical prostatectomy (RARP) is emerging as the standard of care. In order to implement a safe and efficient SDD pathway, it is imperative to appropriately select candidates and have established discharge criteria. We conducted a systematic review and meta-analysis to summarize published pathways, as well as to evaluate the differences in peri-operative characteristics, complication/readmissions rates, and satisfaction/cost data, between in-patient (IP) RARP versus SDD-RARP. Methods: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was prospectively registered with PROSPERO (CRD42021258848). A comprehensive search of PubMed, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), ClinicalTrials.gov, Google Scholar, and conference abstract publications was performed comparing outcomes between IP-RARP and SDD-RARP. A leave-one-out sensitivity analyses was performed to control for heterogeneity and risk of bias. Results: A total of 14 studies (eight prospective and six retrospective cohort studies) were included with a pooled population of 3795 patients, including 2348 (61.9%) IP-RARPs and 1447 (38.1%) SDD-RARPs. SDD pathways varied, though many commonalities were present in patient selection (minimal comorbidities and lived close to the hospital [≤ 50-150 km]), peri-operative recommendations (judicious intra-operative intravenous fluids and short-acting narcotics), and post-operative management (immediate ambulation and diet, and non-narcotic analgesia). When compared to IP-RARP, SDD-RARP had no differences in ≥ Grade 3 Clavien–Dindo complications (RR: 0.4, 95% CI 0.2, 1.1, p = 0.07), 90-day readmission rates (RR: 0.6, 95% CI 0.3, 1.1, p = 0.10), or unscheduled ED visits (RR: 1.0, 95% CI 0.3, 3.1, p = 0.97). Cost savings per patient ranged between $367-2109 (USD), and overall satisfaction was high between 87.5-100%. Conclusions: Same day discharge following RARP is both feasible and safe, with comparable complication and readmission rates to IP-RARP. Additionally, SDD offers healthcare cost-savings with high patient satisfaction rates. Data from this study will further inform the uptake and development of future SDD pathways in contemporary urological care such that it may be offered to a broader patient population.
Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older — United States, 2022
Authors: Neil Murthy, A. Patricia Wodi, Henry Bernstein, Veronica McNally, Sybil Cineas, Kevin Ault
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

At its November 2021 meeting, the Advisory Committee on Immunization Practices* (ACIP) approved the Recommended Adult Immunization Schedule for Ages 19 Years or Older, United States, 2022. The 2022 adult immunization schedule summarizes ACIP recommendations, including several changes to the cover page, tables, and notes from the 2021 immunization schedule.† In addition, the 2022 adult immunization schedule provides an appendix that lists the contraindications to and precautions for all routinely recommended vaccines in the schedule. This schedule can be found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules). Health care providers are advised to use the cover page, tables, notes, and appendix together. This adult immunization schedule is recommended by ACIP (https://www.cdc.gov/vaccines/acip) and approved by CDC (https://www.cdc.gov), the American College of Physicians (https://www.acponline.org), the American Academy of Family Physicians (https://www.aafp.org), the American College of Obstetricians and Gynecologists (https://www.acog.org), the American College of Nurse-Midwives (https://www.midwife.org), the American Academy of Physician Associates (https://www.aapa.org), and the Society for Healthcare Epidemiology of America (https://www.shea-online.org).
A CAR T-inspiring platform based on antibody-engineered exosomes from antigen-feeding dendritic cells for precise solid tumor therapy
Authors: Miao Fan, Huifang Liu, Hongyu Yan, Ruijun Che, Yi Jin, Xinjian Yang, Xiaohan Zhou, Hua Yang, Kun Ge, Xing-Jie Liang, Jinchao Zhang, Zhenhua Li
Journal: Biomaterials (2022)
Successful extraction of hepatic duct calculus using retrieval basket under cholangioscopic guidance
Authors: Mahesh Kumar Goenka, Shivaraj Afzalpurkar, Gajanan Ashokrao Rodge, Usha Goenka
Journal: Endoscopy (2022)

Hepatolithiasis or intrahepatic duct calculi is one of the most complex stone diseases as it poses a great challenge in treatment and also has strong propensity for recurrence. It may be complicated by bile duct strictures, cholangiolytic abscesses, and cholangiocarcinoma [1]. The main endpoint of the treatment for hepatolithiasis would be stone clearance, stricture correction, and restoration of biliary drainage [2].